ESC 2022: First Phase III Results of Targeted KRAS G12C Sotorasib for NSCLC Released with an ORR of 28.1%

KRAS is the most common oncogene, with mutations in a variety of cancers (common cancers such as colon and lung, bile duct, small bowel, skin, bladder and breast, with a rate of pancreatic cancer mutations up to 90%)

The first phase III results of Sotorese's treatment of NSCLC are announced

On August 31, 2022, Amgen announced that the Phase III CodeBreaK 200 clinical study on Sotorasib (AMG-510, trade name: Lumakras) has reached the primary endpoint

Sotorese, the world's first targeted drug

The study, which included 345 patients with KRAS G12C mutation NSCLC who had received at least one platinum-containing chemotherapy and immune checkpoint inhibitor, focused on the efficacy and safety

Preliminary analysis of this trial showed that PFS was 5.

Objective response rate (ORR) in the Sotorese group (28.

There was no significant difference in overall survival (OS) between the two groups (HR=1.

The drug safety was better in the Sotorese group, with a 33.

The findings of the CodeBreaK 200 clinical trial support Sotorese as an important second-line treatment for patients with KRASG12C mutation NSCLC, although there is no significant difference in OS, but there are significant FPS benefits and better safety

The SLATE v1 and SLATE-KRAS cancer vaccines are good news

Cancer vaccines are undoubtedly a major research hotspot in the field of anti-tumor at present, and at ESMO, Gritstone announced the results

The SLATE project is based on Gritstone's proprietary Gritstone EDGE:trade_mark: Artificial Intelligence Platform and Tumor HLA Peptide Sequencing,

Anti-tumor effects

This Phase 1/2 study (NCT03953235) aims to assess the safety, immunogenicity, and early clinical activity

A total of 38 patients with advanced solid tumors participated in this trial, including those using SLATE v1 (n = 26) or SLATE-KRAS (n = 12).

This trial showed good safety in both vaccines, with most TAREs being Grade 1 or Grade 2, SLATE v1 with only 3 TAREs of Grade 3 and above, and SLATS-KRAS not reporting TAREs of Grade 3 and above

The KRAS target has attracted much attention since its discovery, and the research progress on KRAS released on ESMO has brought new surprises to the field of tumor treatment, and it is expected that there will be more applications

References:

1.

2.
Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) at ESMO 2022 | Gritstone bio